Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margi...
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune dise...
Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced th...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial...
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high t...
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s p...
NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 Belite Bio, Inc. (NASDAQ...
To equip users with a complete next generation sequencing (NGS) solution from sample to answer, global genomics leader Integrated DNA Technologies (IDT),...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events re...
Avobis Bio LLC, a clinical-stage company developing implantable cell therapies, announced that the U.S. Food and Drug Administration ("FDA") has gr...
Leo Cancer Care announced that it has placed orders for TibaRay's advanced linear accelerators (linacs), which will be evaluated as an upgrade option to th...
© 2025 Biopharma Boardroom. All Rights Reserved.
